The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation offers a synopsis of upcoming projects from the Novo Nordisk Foundation.

According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.

Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.

The council was established as part of NORD’s Project RDAC.

Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.

In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation, offers her thoughts on where quantum sensing is heading when it comes to aiding treatment development and clinical studies.

The latest news for pharma industry insiders.

With a final decision expected next February, MenABCWY combines the protective elements of GSK’s existing vaccines to target the five primary serogroups of Neisseria meningitidis.

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.

In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation discusses a recent grant awarded to the Copenhagen Center for Biomedical Quantum Sensing.

BrandShield states that it has identified sites selling counterfeit versions of Wegovy and Ozempic, among other drugs.

The latest news for pharma industry insiders.

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.

Butta discusses how new technologies are being implemented in at-home devices.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses what to expect from the obesity space in the next five years.

Tava’s network of therapists will be added to Health Advocate’s existing network.

The latest news for pharma industry insiders.

Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in ensuring that patients have access to the medicines they need.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses why their drug isn't experiencing the same supply issues as the bigger names in the space.

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.

Users will be able to access DeepScribe’s documentation platform through AWS.